A new study from Cleveland Clinic offers hope for glioblastoma patients facing recurrence by identifying which ones are most likely to benefit from a targeted radiation treatment called stereotactic radiosurgery (SRS). Researchers analyzed 49 patients treated with Gamma Knife SRS between 2010 and 2024 and found that patients with certain favorable genetic and clinical features experienced a median survival of 15.1 months after treatment, compared to just 7.6 months for those without these markers. This nearly twofold difference could help doctors make smarter treatment decisions for one of the most aggressive brain cancers. What Makes Some Glioblastoma Patients Better Candidates for Radiation Surgery? Glioblastoma is notoriously difficult to treat because it almost always comes back, even after initial surgery and chemotherapy. For decades, doctors debated whether SRS, a high-dose, focused radiation technique, was worth using at the time of recurrence. A landmark 2004 trial suggested it wasn't helpful when added upfront, so many hospitals stopped using it for this cancer. But that study left a critical question unanswered: could SRS help patients whose tumors had already returned, especially if those patients had specific characteristics that made them more likely to respond ? The Cleveland Clinic team decided to find out by examining which patients actually benefited. They looked at genetic and molecular data collected at the time of initial diagnosis, then tracked how patients fared after SRS treatment. The researchers focused on biomarkers that any modern hospital treating glioblastoma would routinely collect, making their findings broadly applicable. Which Specific Factors Predict Better Outcomes After Radiation Surgery? The study identified several independent predictors of survival and disease control. Patients with smaller tumors, longer time between initial diagnosis and recurrence, and specific genetic features showed the most promise. The researchers discovered that a chromosome region called 19q13 played a particularly important role. Patients whose tumors retained this region, rather than losing it, had better survival outcomes. This region contains tumor suppressor genes that may make cancer cells more vulnerable to the concentrated radiation delivered by SRS. The power of these findings became clear when researchers combined multiple favorable factors. Here are the key predictors that independently improved outcomes: - Tumor Size: Tumors measuring 2 cubic centimeters or smaller were significantly more likely to respond well to SRS treatment. - Time to Recurrence: Patients whose cancer returned more than 8 months after initial diagnosis had better survival rates than those with earlier recurrence. - Chromosome 19q13 Status: Tumors that retained the 19q13 chromosomal region, indicating no loss of tumor suppressor genes, showed improved overall survival. - Cell Proliferation Rate: Counterintuitively, tumors with a high Ki-67 index (above 50%), indicating rapid cell division, were associated with better progression-free survival, possibly because fast-growing cells are more susceptible to radiation damage. - P53 Protein Expression: Higher levels of p53 staining (30% or above) correlated with improved progression-free survival. When patients had at least two of these favorable markers, their median survival jumped to 15.1 months after SRS, compared to 7.6 months for those with fewer markers. For progression-free survival, those with two or more favorable factors survived a median of 6.7 months without disease progression, versus 2.8 months for those with fewer markers. How to Identify Candidates for Stereotactic Radiosurgery in Glioblastoma Based on these findings, clinicians can now use a more targeted approach to patient selection. Here are the practical steps doctors should consider: - Assess Tumor Volume: Use imaging to measure recurrent tumors and identify those at or below the 2 cubic centimeter threshold, which represents the optimal size for SRS treatment. - Review Disease Timeline: Calculate the interval between initial diagnosis and recurrence; patients with more than 8 months between these events are better candidates for SRS. - Obtain Molecular Testing: Request genetic analysis of the tumor at initial diagnosis, specifically looking at chromosome 19q13 status, Ki-67 index, and p53 expression levels to stratify risk. - Discuss at Multidisciplinary Tumor Board: Present cases with favorable markers to a team of neurosurgeons, radiation oncologists, and neuro-oncologists to confirm SRS is the right choice. - Consider Quality of Life: Emphasize to patients that SRS is an outpatient procedure with minimal toxicity compared to chemotherapy, offering potential survival benefit without the side effects. Interestingly, one traditional marker called MGMT promoter methylation, which is very important for predicting outcomes at initial diagnosis, did not independently predict survival after SRS in this study. This suggests that the biology of recurrent tumors may differ from newly diagnosed ones, and doctors should not rely solely on MGMT status when deciding on salvage radiation therapy. "Glioblastoma has a poor prognosis, and many systemic treatments cause serious side effects. If a recurrence is small and in one area, and we can offer a high-dose treatment that might extend survival without affecting quality of life, we owe it to patients to explore that option," explained Lilyana Angelov, MD, Director of Cleveland Clinic's Gamma Knife Center. Lilyana Angelov, MD, Director of Cleveland Clinic's Gamma Knife Center Why This Matters for Brain Tumor Patients and Their Families Glioblastoma remains one of the most aggressive brain cancers, with historically poor survival rates. The median survival from initial diagnosis is often measured in months, not years. By identifying patients who can achieve 15.1 months of survival after recurrence, this research offers a meaningful extension of life. Equally important, many of these patients maintained their neurological function, meaning they avoided the weakness, speech difficulties, and cognitive decline that often accompany tumor progression. The study was limited by its retrospective design and relatively small sample size of 49 patients with 83 distinct lesions. However, the researchers emphasized the need for prospective clinical trials to confirm these findings. Despite these limitations, the work provides actionable guidance that clinicians can implement immediately using standard diagnostic tools available at any modern hospital. "These findings are encouraging because they demonstrate that this essentially noninvasive outpatient therapy, when used in appropriately selected patients, confers a meaningful increase in post-recurrence survival. A good portion of this extended survival comes with maintenance of neurological function, that is, without disease progression that can lead to weakness, speech difficulties and related challenges. What's more, these benefits come with limited to no associated toxicity compared with alternatives such as chemotherapy. For these patients, it's a win in terms of both quantity and quality of life," noted Dr. Angelov. Lilyana Angelov, MD, Director of Cleveland Clinic's Gamma Knife Center For patients and families facing a glioblastoma recurrence, this research suggests that molecular testing and careful patient selection can help identify who will benefit most from SRS. Rather than viewing this treatment as a one-size-fits-all approach, doctors can now use specific genetic and clinical markers to predict which patients are most likely to experience meaningful survival gains. The key takeaway is that precision medicine, informed by molecular data, is transforming how we approach even the most challenging brain cancers.
